The P-III (SEQUOIA-HCM) study investigates the safety, efficacy, and quantitative understanding of obstruction impact of aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy (HCM)
The results revealed that aficamten improved exercise capacity vs PBO and increased the peak oxygen uptake (pVO2) by a least square mean difference of 1.74 (1.04 – 2.44) mL/kg/min
Furthermore, improvements were also seen in 10 2EPs incl. Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), NYHA functional class improvement, change in provoked LVOT-G, proportion with LVOT-G <30 mmHg at wks. 12 & 24, exercise workload, and guideline-eligibility for septal reduction therapy
Ref: Cytokinetics | Image: Cytokinetics
Related News:- Cytokinetics Initiates P-III (SEQUOIA-HCM) Trial of Aficamten for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
